CN113337453A - Method for detecting pulmonary toxicity of compounds - Google Patents
Method for detecting pulmonary toxicity of compounds Download PDFInfo
- Publication number
- CN113337453A CN113337453A CN202110598316.5A CN202110598316A CN113337453A CN 113337453 A CN113337453 A CN 113337453A CN 202110598316 A CN202110598316 A CN 202110598316A CN 113337453 A CN113337453 A CN 113337453A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- alveolar
- inducing
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 25
- 206010061924 Pulmonary toxicity Diseases 0.000 title claims abstract description 16
- 231100000374 pneumotoxicity Toxicity 0.000 title claims abstract description 16
- 230000007047 pulmonary toxicity Effects 0.000 title claims abstract description 12
- 210000004072 lung Anatomy 0.000 claims abstract description 75
- 241000282414 Homo sapiens Species 0.000 claims abstract description 44
- 230000004069 differentiation Effects 0.000 claims abstract description 31
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 24
- 231100000419 toxicity Toxicity 0.000 claims abstract description 9
- 230000001988 toxicity Effects 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 186
- 239000002243 precursor Substances 0.000 claims description 72
- 230000001939 inductive effect Effects 0.000 claims description 25
- 239000000090 biomarker Substances 0.000 claims description 18
- 210000004039 endoderm cell Anatomy 0.000 claims description 18
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 17
- 210000001811 primitive streak Anatomy 0.000 claims description 16
- 230000006698 induction Effects 0.000 claims description 14
- 101001081582 Homo sapiens DNA-binding protein inhibitor ID-2 Proteins 0.000 claims description 13
- 101000612671 Homo sapiens Pulmonary surfactant-associated protein C Proteins 0.000 claims description 13
- 101150111110 NKX2-1 gene Proteins 0.000 claims description 13
- 210000001700 mitochondrial membrane Anatomy 0.000 claims description 13
- 102100040971 Pulmonary surfactant-associated protein C Human genes 0.000 claims description 10
- 230000003833 cell viability Effects 0.000 claims description 10
- 238000010186 staining Methods 0.000 claims description 9
- 101000581940 Homo sapiens Napsin-A Proteins 0.000 claims description 8
- 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 claims description 8
- 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 7
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 claims description 6
- 102100027642 DNA-binding protein inhibitor ID-2 Human genes 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 2
- 230000003185 calcium uptake Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 231100001160 nonlethal Toxicity 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- -1 tetramethyl rhodamine methyl ester Chemical class 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 7
- 239000003344 environmental pollutant Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 22
- 239000007640 basal medium Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 17
- 239000002609 medium Substances 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 10
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 7
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 108010023082 activin A Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 102100027343 Napsin-A Human genes 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 4
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 4
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 4
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 4
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 4
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- XHBVYDAKJHETMP-UHFFFAOYSA-N dorsomorphin Chemical compound C=1C=C(C2=CN3N=CC(=C3N=C2)C=2C=CN=CC=2)C=CC=1OCCN1CCCCC1 XHBVYDAKJHETMP-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003570 cell viability assay Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000613 environmental toxicology Toxicity 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0688—Cells from the lungs or the respiratory tract
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a method for detecting the toxicity of a compound to human lungs, which uses a human pluripotent stem cell lung differentiation model to simulate the real situation in a human body and can efficiently and accurately evaluate the toxicity of the compound to the human lungs. The method can be used as an effective means for evaluating the pulmonary toxicity of PM2.5 and other environmental pollutants, and can also be used for evaluating the pulmonary toxicity of preclinical medicines, so that the risk of clinical experiment failure is reduced.
Description
Technical Field
The invention belongs to the cross field of cell biology and environmental toxicology, and relates to a method for detecting the lung toxicity of a compound.
Background
With the development of world science and technology and the improvement of industry, a large amount of substances with unknown toxicity are continuously discharged into the environment, wherein a part of substances can be dissociated in the air or form haze, and further transmitted through the air and inhaled by a human body to cause adverse effects on the health of the human body. Therefore, there is a need for an effective research means for evaluating the effect of compounds on human lung, preventing and preventing the toxic air pollutants from harming human health.
Most of the previous lung toxicity researches depend on animal models or lung cancer cell models, however, animal experiment operation is difficult, experiment amount is large, and cross-species differences exist when results are extrapolated to human beings; cancer cell test since the test material is a cell that has become cancerous, it is impossible to objectively respond to the toxicity of the compound to normal cells. In addition, the method of directly isolating alveolar cells from human body as research material is also difficult, and although some experimental procedures for isolating alveolar epithelial precursor cells from human fetus have been reported in the prior art, alveolar epithelial precursor cells usually appear from 26 weeks of pregnancy, where no sample can be obtained unless spontaneous abortion occurs, and neither purification nor extensive culture techniques of alveolar epithelial cells are mature.
Therefore, there is a need for a method of testing compounds for pulmonary toxicity that at least partially addresses the above-mentioned problems.
Disclosure of Invention
The human pluripotent stem cells are sub-totipotent stem cells which can be proliferated almost indefinitely and keep normal karyotypes, a large number of human lung precursors or lung epithelial cells can be obtained by expanding and culturing the human pluripotent stem cells and then inducing the human pluripotent stem cells to differentiate, and the cells not only can meet the requirement of high-throughput toxicology screening in quantity, but also are normal human cells, so that the cells are very suitable for researching the human lung toxicity of compounds.
Therefore, an object of the present invention is to provide a highly efficient and accurate in vitro method for detecting pulmonary toxicity in human, wherein the detection is performed by using human pluripotent stem cell-induced lung precursor cells or alveolar cells.
The invention provides the following technical scheme:
in one aspect, the invention provides lung precursor cells induced by induced human pluripotent stem cells.
In some embodiments, the lung precursor cells are induced from induced human pluripotent stem cells by the following induction phase:
a. inducing the human pluripotent stem cells to differentiate into primitive streak cells;
b. inducing the primitive streak cells to differentiate into definitive endoderm cells;
c. inducing definitive endoderm cells to differentiate into head foregut cells;
d. inducing differentiation of the head foregut cells into lung precursor cells.
In some embodiments, the basal medium used to induce differentiation is DMEM/F12 medium containing 1 XGlutaMAX, 1 Xpenicillin-streptomycin, 1 XN 2 supplement, 1 XB 27 supplement, and ascorbic acid at 40-60 μ g/mL, preferably 40, 50, 60 μ g/mL, more preferably 50 μ g/mL.
In some embodiments, the medium used to induce differentiation of human pluripotent stem cells into primitive streak cells is the above-described basal medium to which Activin A (20-500ng/mL, preferably 20, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500ng/mL, more preferably 100ng/mL) and CHIR99021 (1-12. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. mu.M, more preferably 3. mu.M) are added.
In some embodiments, the induction time to induce differentiation of human pluripotent stem cells into primitive streak cells is 1-3 days, preferably 1, 2, 3 days, more preferably 1 day.
In some embodiments, the medium used to induce differentiation of primitive streak cells into definitive endoderm cells is the basal medium described above to which Activin A (20-500ng/mL, preferably 20, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500ng/mL, more preferably 100ng/mL) is added.
In some embodiments, the medium used to induce the differentiation of definitive endoderm cells into head foregut cells is the basal medium described above to which SB431542 (1-20. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20. mu.M, more preferably 10. mu.M) and dorsomorphin (1-10. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. mu.M, more preferably 2. mu.M) are added.
In some embodiments, the induction time to induce definitive endoderm cells to differentiate into head foregut cells is 2-4 days, preferably 2, 3, 4 days, and more preferably 3 days.
In some embodiments, the medium used to induce differentiation of the head foregut cells into lung precursor cells is the basal medium described above to which CHIR99021 (1-12. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. mu.M, more preferably 3. mu.M), retinoic acid (10-100nM, preferably 10, 20, 30, 40, 50, 60, 70, 80, 90, 100nM, more preferably 50nM), BMP4(1-30ng/mL, preferably 1, 5, 8, 15, 20, 25, 30ng/mL, more preferably 10ng/mL), FGF7 (10-50/mL, preferably 10, 15, 20, 25, 30, 35, 40, 45, 50ng/mL, more preferably 10ng/mL), FGF 26 (10-50ng/mL, preferably 10, 15, 20, 25, 30, 40, 45, 50ng/mL, more preferably 10ng/mL), FGF10(10-50ng/mL, preferably 10, 15, 20, 25, 30, 35. 40, 45, 50ng/mL, more preferably 10 ng/mL).
In some embodiments, the induction time to induce differentiation of the head foregut cells into lung precursor cells is 8-10 days, preferably 8, 9, 10 days, more preferably 9 days.
In another aspect, the present invention provides an alveolar cell induced by an induced human pluripotent stem cell.
In some embodiments, the alveolar cells are induced by inducing human pluripotent stem cells through the following induction stages:
a. inducing the human pluripotent stem cells to differentiate into primitive streak cells;
b. inducing the primitive streak cells to differentiate into definitive endoderm cells;
c. inducing definitive endoderm cells to differentiate into head foregut cells;
d. inducing differentiation of the head foregut cells into lung precursor cells.
e. Inducing lung precursor cells to differentiate into alveolar cells.
In some embodiments, the basal medium used to induce differentiation is DMEM/F12 medium containing 1 XGlutaMAX, 1 Xpenicillin-streptomycin, 1 XN 2 supplement, 1 XB 27 supplement, and ascorbic acid at 40-60 μ g/mL, preferably 40, 50, 60 μ g/mL, more preferably 50 μ g/mL.
In some embodiments, the medium used to induce differentiation of human pluripotent stem cells into primitive streak cells is the above-described basal medium to which Activin A (20-500ng/mL, preferably 20, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500ng/mL, more preferably 100ng/mL) and CHIR99021 (1-12. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. mu.M, more preferably 3. mu.M) are added.
In some embodiments, the induction time to induce differentiation of human pluripotent stem cells into primitive streak cells is 1-3 days, preferably 1, 2, 3 days, more preferably 1 day.
In some embodiments, the medium used to induce differentiation of primitive streak cells into definitive endoderm cells is the basal medium described above to which Activin A (20-500ng/mL, preferably 20, 50, 80, 100, 150, 200, 250, 300, 350, 400, 450, 500ng/mL, more preferably 100ng/mL) is added.
In some embodiments, the medium used to induce the differentiation of definitive endoderm cells into head foregut cells is the basal medium described above to which SB431542 (1-20. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20. mu.M, more preferably 10. mu.M) and dorsomorphin (1-10. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. mu.M, more preferably 2. mu.M) are added.
In some embodiments, the induction time to induce definitive endoderm cells to differentiate into head foregut cells is 2-4 days, preferably 2, 3, 4 days, and more preferably 3 days.
In some embodiments, the medium used to induce differentiation of the head foregut cells into lung precursor cells is the basal medium described above to which CHIR99021 (1-12. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. mu.M, more preferably 3. mu.M), retinoic acid (10-100nM, preferably 10, 20, 30, 40, 50, 60, 70, 80, 90, 100nM, more preferably 50nM), BMP4(1-30ng/mL, preferably 1, 5, 8, 15, 20, 25, 30ng/mL, more preferably 10ng/mL), FGF7 (10-50/mL, preferably 10, 15, 20, 25, 30, 35, 40, 45, 50ng/mL, more preferably 10ng/mL), FGF 26 (10-50ng/mL, preferably 10, 15, 20, 25, 30, 40, 45, 50ng/mL, more preferably 10ng/mL), FGF10(10-50ng/mL, preferably 10, 15, 20, 25, 30, 35. 40, 45, 50ng/mL, more preferably 10 ng/mL).
In some embodiments, the induction time to induce differentiation of the head foregut cells into lung precursor cells is 8-10 days, preferably 8, 9, 10 days, more preferably 9 days.
In some embodiments, the medium used to induce differentiation of lung precursor cells into alveolar cells is the above-described basal medium supplemented with CHIR99021 (1-12. mu.M, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. mu.M, more preferably 3. mu.M), FGF7(10-50ng/mL, preferably 10, 15, 20, 25, 30, 35, 40, 45, 50ng/mL, more preferably 10ng/mL), dexamethasone (10-50nM, preferably 10, 15, 20, 25, 30, 35, 40, 45, 50nM, more preferably 50nM), cAMP (0.1-2mM, preferably 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 0.9, 1.0, 1.1.1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.1.8, 1.9, 1.2, 1.3, 1.4, 1.3, 1.9, 1.8, 1.0.0.0.0.9, 1.9, 1.0.0.0.0.0.9, 1.1.1.2, 1, 1.9, 1.1.2, 1.3, 1.4, 1.9, 1.4, 1.9, or more preferably 1.4, or 1.0.4, or 1.0.1.1.1.1.1.1.4, or more preferably 1.1.1.1.1.1.2 mM, or more preferably 1.2 mM, or more preferably 1.0.1.1.1.0.0.0.0 mM, or 1mM, or more preferably 1.0.0.0.0 mM, or 1.3, or more preferably 1mM, or 1.0.0.0.0.0.3, or more preferably 1mM, or 1.3, or more preferably 1mM, or more preferably 1.1.3, or more preferably 1.3, or more preferably 1mM, or more preferably 1.0.0.0.0.0.0.0 mM, or more preferably 1.1.1.1.1.1.1 mM, or more preferably 1.0.0.0.0.3, or more preferably 1.3, or more preferably 1.1.0.0.0.0.3, or more preferably 1.3, or more preferably 1.1.0.0.0.0.0.0.0.0.0.3, or more preferably 1.3, or more preferably 1.1.3, or more, preferably 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0mM, more preferably 0.1 mM).
In some embodiments, the induction time to induce differentiation of lung precursor cells into alveolar cells is 13-15 days, preferably 13, 14, 15 days, more preferably 14 days.
In another aspect, the invention provides the use of a lung precursor cell or an alveolar cell as described above for detecting pulmonary toxicity of a compound.
In another aspect, the present invention provides a method of detecting pulmonary toxicity of a compound, the method comprising the steps of:
s1, inducing human pluripotent stem cells to differentiate into lung precursor cells or alveolar cells;
s2. treating the lung precursor cells or alveolar cells with a compound at a concentration of 1nM to 1mM, preferably 10nM, 50nM, 100nM, 500nM, 1. mu.M, 5. mu.M and 10. mu.M for 1 to 8 days, preferably for 1, 2, 3, 4, 5, 6, 7, 8 days, more preferably for 2 days, 8 days;
s3, detecting the concentration of the compound which can affect the basic toxicity index of lung precursor cells or alveolar cells;
s4, detecting the change of the lung precursor cell or alveolar cell biomarker under non-lethal concentration.
In some embodiments, the basal toxicity index is selected from one or more of the group consisting of cell viability, mitochondrial membrane integrity, active oxygen production, calcium flux changes, and lactate dehydrogenase leakage, preferably cell viability and mitochondrial membrane integrity.
In some embodiments, the method of detecting cell viability is selected from the group consisting of resazurin, MTT, live/dead cell counting assays, and preferably resazurin.
In some embodiments, the method of detecting mitochondrial membrane integrity is selected from the group consisting of JC-1 staining, tetramethyl rhodamine methyl ester staining, acridine orange 10-bromononane staining, preferably JC-1 staining.
In some embodiments, the biomarker of lung precursor cells or alveolar cells is selected from the group consisting of NKX2.1, ID2, SFTPC, ABCA3, and NAPSA genes.
In some embodiments, the biomarker for lung precursor cells is selected from the group consisting of NKX2.1, ID2 and SFTPC.
In some embodiments, the biomarker of alveolar cells is selected from the group consisting of NKX2.1, ID2, SFTPC, ABCA3, and NAPSA genes.
In some embodiments, the method of detecting a change in a lung precursor cell or alveolar cell biomarker comprises fluorescent quantitative PCR.
Compared with the prior art, the invention has the following advantages:
1. the invention provides a feasible and reliable human lung toxicity research method.
2. Normal human lung cells are extremely difficult to obtain and therefore cannot be used for toxicology studies. The invention is based on the induced human pluripotent stem cell lung differentiation model, can easily obtain a large amount of normal human lung cells, can solve the source problem of the human lung cells, and lays a foundation for high-throughput accurate detection of pulmonary toxicity.
3. Compared with cancer cell experiments, the invention uses normal cells, which is closer to the real situation of healthy human body.
4. Compared with animal experiments, the method has the advantages of low cost, short time consumption, real-time monitoring and easy control of external factor influence.
Drawings
FIG. 1 is a lung precursor cell morphology according to an embodiment of the invention;
FIG. 2 is an alveolar cell morphology according to an embodiment of the present invention;
FIG. 3 is a graph of the effect of benzopyrene on lung precursor cell viability, p <0.05, p <0.01, t-test analysis, according to an embodiment of the present invention;
FIG. 4 is a graph of the effect of benzopyrene on alveolar cell viability, p <0.05, p <0.01, t-test analysis, according to an embodiment of the present invention;
FIG. 5 is a graph of the effect of benzopyrene on mitochondrial membrane integrity of lung precursor cells according to an embodiment of the present invention, p <0.05, p <0.01, t-test analysis;
FIG. 6 is a graph of the effect of benzopyrene on alveolar cell mitochondrial membrane integrity, p <0.05, p <0.01, t-test analysis, according to an embodiment of the present invention;
FIG. 7 is a graph of the effect of benzopyrene on the lung precursor cell biomarker NKX2.1, according to an embodiment of the present invention;
FIG. 8 is a graph of the effect of benzopyrene on the lung precursor cell biomarker ID2, according to an embodiment of the present invention;
FIG. 9 is a graph of the effect of benzopyrene on the lung precursor cell biomarker SFTPC according to an embodiment of the present invention;
FIG. 10 is a graph of the effect of benzopyrene on the alveolar cell biomarker NKX2.1, in accordance with an embodiment of the present invention;
FIG. 11 is a graph of the effect of benzopyrene on alveolar cell biomarker ID2, according to an embodiment of the present invention;
FIG. 12 is a graph of the effect of benzopyrene on the alveolar cell biomarker SFTPC, in accordance with an embodiment of the present invention;
FIG. 13 is a graph of the effect of benzopyrene on the alveolar cell biomarker ABCA3, according to an embodiment of the present invention;
FIG. 14 is a graph of the effect of benzopyrene on the alveolar cell biomarker NAPSA, according to an embodiment of the present invention.
Detailed Description
In order that the objects, technical solutions and advantages of the present invention will become more apparent, the present invention will be further described in detail with reference to the accompanying drawings in conjunction with the following specific embodiments.
Example 1 Induction of differentiation of human pluripotent Stem cells into definitive endoderm cells
All cells of the present invention were incubated at 37 ℃ in a cell incubator containing 5% carbon dioxide.
The initial cell used in the present invention is induced human pluripotent stem cell DYR0100 (Chinese academy of sciences cell bank/stem cell technology platform, SCSP-1301). DYR0100 was maintained in matrigel (Corning, 356231) -coated 24-well plates using 10mL of mTesR1(stem cell Technologies, 85850) medium. When the confluency of DYR0100 clone reached 90%, differentiation was induced.
The basal medium used for inducing differentiation in the present invention was 100mL of DMEM/F12(Gibco, C1410500BT330500BT) medium supplemented with 1mL of 100 XGlutaMAX (Gibco, 35050061), 1mL of 100 Xpenicillin-streptomycin (Gibco, 15140163), 1mL of 100 XN 2 supplement (Gibco, 17502001), 2mL of 50 XB 27 supplement (Gibco, 17504044), and 0.1mL of 50mg/mL ascorbic acid (original leaf, S24742).
On day 0 of differentiation, 100ng/mL Activin A (Peprotech, 120-14E) and 3. mu.M CHIR99021(Selleck, S2924) were added to the basal medium to induce differentiation of the cells into primitive streak cells.
On day 1 of differentiation, 100ng/mL Activin A was added to the basal medium to induce primitive streak cells to differentiate for 3 days, and definitive endoderm cells were obtained.
The definitive endoderm obtained by the invention is a dense monolayer of cells.
EXAMPLE 2 Induction of definitive endoderm differentiation into Lung precursor cells
Definitive endoderm cells finally obtained in example 1 were used.
The definitive endoderm cells obtained in example 1 were induced to differentiate for 3 days into foregut cells by adding 10. mu.M of SB431542(Selleck, S2924) and 2. mu.M of dorsomorphin (Selleck, S7306) to the basal medium.
mu.M CHIR99021, 50nM retinoic acid (Sigma, R2625), 10ng/mL BMP4(Gibco, PHC9531), 10ng/mL FGF7(R & D, 251-KG-050), and 10ng/mL FGF10(R & D, 345-FG-025) were added to the basal medium, and the above-obtained anterior enterocytes were induced to differentiate for 9 days into lung precursor cells (FIG. 1).
Example 3 Induction of differentiation of Lung precursor cells into alveolar cells
The lung precursor cells finally obtained in example 2 were used.
mu.M CHIR99021, 10ng/mL FGF7, 50nM dexamethasone, 0.1mM cAMP (Sigma-Aldrich, B5386) and 0.1mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich, I5879-250MG) were added to the basal medium to induce the lung precursor cells obtained in example 2 to differentiate for about 16 days, and finally become alveolar cells (FIG. 2).
Example 4 treatment of Lung precursor cells with Compounds
The lung precursor cells finally obtained in example 2 were used.
The lung precursor cells obtained in example 2 were digested with TryplE, and the cells were seeded in a matrigel-coated 96-well plate in an amount of 15,000 cells per square centimeter. Lung precursor cells were cultured in a basal medium supplemented with 3. mu.M CHIR99021, 50nM retinoic acid, 10ng/mL BMP4, 10ng/mL FGF7, 10ng/mL FGF10 and the compound.
The compound used is benzopyrene (BaP) which is the main component of the atmospheric pollutants.
The assay was performed using 96-well plates, with BaP concentrations in the medium of 1, 5, 10, 50, 100, 500 and 1000nM, respectively, and controls treated with DMSO.
Example 5 treatment of Lung precursor cells with Compounds
Example 5 was the same as example 4 except that 24-well plates were used for the culture and the BaP concentration in the medium was 10, 50, 100nM, and the control was also treated with DMSO.
Example 6 treatment of alveolar cells with Compounds
The alveolar cells finally obtained in example 3 were used.
Alveolar cells obtained in example 3 were digested with TryplE, and the cells were seeded in matrigel-coated 96-well plates in an amount of 15,000 cells per square centimeter. Alveolar cells were cultured in basal medium supplemented with 3. mu.M CHIR99021, 10ng/mL FGF7, 50nM dexamethasone, 0.1mM cAMP, 0.1mM 3-isobutyl-1-methylxanthine and compound.
The compound used was BaP.
The assay was performed using 96-well plates, with BaP concentrations in the medium of 1, 5, 10, 50, 100, 500 and 1000nM, respectively, and controls treated with DMSO.
Example 7 treatment of alveolar cells with Compounds
Example 7 was the same as example 6 except that 24-well plates were used for the culture and the BaP concentration in the medium was 10nM, 50nM, 100nM, and the control was also treated with DMSO.
Example 8 cell viability assay of Lung precursor cells and alveolar cells
Since normal human alveoli generally contain lung precursor cells and alveolar cells, lung precursor cells and alveolar cells obtained by induced differentiation are preferred as a test model for detecting the pulmonary toxicity of a compound. The cytotoxicity of the compound generally causes the reduction of the cell number or the functional damage, and the health condition of the cell (whether the cell activity is damaged) and the existence of the apoptosis precursor (whether the mitochondrial membrane potential is reduced) can be simply, conveniently and quickly known by detecting the cell activity and the mitochondrial membrane potential. In this example, the compound was selected to be the main component of air pollutants, BaP, and the lung precursor cells of example 4 and alveolar cells of example 6 were washed once with DPBS after 2 days of BaP treatment. To the DPBS-washed cell culture plate, 100. mu.L of resazurin cell viability assay working solution (basal medium containing 10. mu.M resazurin) was added, and the mixture was incubated in a carbon dioxide incubator at 37 ℃ for 1 hour. The fluorescence of the resazurin-treated cells was measured using a Varioskan LUX multi-functional microplate reader. The fluorescence is 590nm fluorescence emitted by each well under excitation of 530nm light. Fluorescence detection results show that more than 1 μ M benzopyrene can inhibit cell viability of lung precursor cells (as shown in FIG. 3), and more than 5 μ M benzopyrene can inhibit cell viability of alveolar cells (as shown in FIG. 4). The above results indicate that lung precursor cells are more sensitive to benzopyran treatment than terminally differentiated alveolar cells. Since current stem cell toxicology studies show that precursor cells of the same lineage tend to respond more strongly to environmental signals than terminally differentiated cells, the phenomenon in figure 4 is more reasonable.
Example 9 mitochondrial Membrane integrity assays of Lung precursor cells and alveolar cells
Since the compound concentration at μ M level tends to show toxicity at 0.5-2 days, the lung precursor cells of example 4 and the alveolar cells of example 6 were treated with benzopyrene for 0.5-2 days, preferably 0.5, 1, 1.5, 2 days, and for 2 days in this example. After treatment, cells were washed once with DPBS. To the DPBS-washed cell culture plates, the same volume of basal medium containing 2. mu.g/mL JC-1 dye was added per well and incubated in a carbon dioxide incubator at 37 ℃ for 30 min. The supernatant of the JC-1 stained cells was discarded and an equal volume of basal medium was added again. The JC-1 stained cells were examined for green fluorescence at 490/530nm and red fluorescence at 525/590nm using a Varioskan LUX multifunctional microplate reader. The green fluorescence shows free JC-1 in the cytoplasm and the red fluorescence shows the aggregated JC-1 in intact mitochondria. JC-1 staining results show that the benzopyrene treatment of more than 1 μ M of lung precursor cells can reduce the mitochondrial membrane potential of the lung precursor cells, the benzopyrene treatment of more than 5 μ M can reduce the mitochondrial membrane potential of the alveolar cells, which suggests that 1 μ M of benzopyrene can cause mitochondrial damage of the lung precursor cells, 5 μ M of benzopyrene can cause mitochondrial damage of the alveolar cells, and the results are similar to the results obtained by cell viability detection, and the lung precursor cells with stem cell characteristics are more sensitive to the benzopyrene treatment.
Example 10 detection of Lung precursor cell biomarkers
The lung precursor cells of example 5 and the alveolar cells of example 7 are treated with benzopyrene for 1, 2, 3, 4, 5, 6, 7 and 8 days, and the supernatant is discarded after 8 days in this example to amplify the toxic effect and ensure a short experimental period.
The RNA of the compound-treated sample was extracted using TRNzol Total RNA extraction reagent (DP 424, Tiangen Biochemical technology, Inc., Beijing).
Genomic DNA contamination and reverse transcription in the samples were removed using the FastKing kit (Tiangen Biochemical technology (Beijing) Ltd., KR 118).
The samples were subjected to fluorescent quantitative PCR using FastFire qPCR PreMix (tiangen biochemistry technologies (beijing) ltd., FP 207).
The primers used in the fluorescent quantitative PCR experiment are designed according to the human genome transcript information published by NCBI, the product length is about 80-120 bp, and the PCR primer information is as follows:
GAPDH-Fw:5′-GGTCACCAGGGCTGCTTTTA-3′
GAPDH-Rv:5′-GGATCTCGCTCCTGGAAGATG-3′
NKX2.1-Fw:5′-CTCATGTTCATGCCGCTC-3′
NKX2.1-Rv:5′-GACACCATGAGGAACAGCG-3′
ID2-Fw:5′-GACAGCAAAGCACTGTGTGG-3′
ID2-Rv:5′-TCAGCACTTAAAAGATTCCGTG-3′
SFTPC-Fw:5′-AGCAAAGAGGTCCTGATGGA-3′
SFTPC-Rv:5′-CGATAAGAAGGCGTTTCAGG-3′
ABCA3-Fw:5′-AAGATGTAGCGGACGAGAGG-3′
ABCA3-Rv:5′-CCCCGGTCAGCATTTTGAAA-3′
NAPSA-Fw:5′-ACGCCTCCACAAAACTTCAC-3′
NAPSA-Rv:5′-TGGCAAACTTGGTCCCATTG-3′
the reaction conditions of the fluorescent quantitative PCR are as follows: pre-denaturation at 95 ℃ for 30 seconds; 95 deg.C, 5 seconds, 60 deg.C, 30 seconds, 50 cycles.
The expression levels of marker genes NKX2.1, ID2 and SFTPC were detected in lung precursor cells using fluorescent quantitative PCR. The results of the correlation measurements are shown in FIGS. 7-9. The experimental results show that BaP treatment can inhibit the expression of transcription factors NKX2.1, ID2 and a lung surfactant protein coding gene SFTPC in lung precursor cells, and the inhibition effect shows a dose-dependent enhancement trend. The inhibition of the key transcription factors NKX2.1, ID2 and important lung surfactant protein coding gene SFTPC by BaP shows that the BaP has great influence on the function of lung precursor cells.
Since alveolar cells are differentiated from lung precursor cells, NKX2.1, ID2 and SFTPC genes are also expressed in alveolar cells, and thus, they are also used as markers of alveolar cells under study, and furthermore, alveolar cells have unique markers ABCA3 and NAPSA. Thus, this example uses fluorescent quantitative PCR to detect the expression levels of alveolar cell marker genes NKX2.1, ID2, SFTPC, ABCA3, and NAPSA. The results of the correlation measurements are shown in FIGS. 10-14. From the results, it can be seen that the expression levels of NKX2.1, ID2, SFTPC, ABCA3 and NAPSA all showed a dose-dependent decrease trend with an increase in BaP concentration, suggesting that BaP inhibits the expression of the above genes in which NAPSA encodes a protease required for lung surfactant protein maturation and ABCA3 encodes an important transporter associated with lung active protein secretion. Changes in the expression levels of the relevant genes suggest that BaP exposure inhibits the synthesis and transport of lung surfactant proteins, thereby impairing alveolar cell function.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are only exemplary embodiments of the present invention and are not intended to limit the present invention, and any modifications, equivalents, improvements and the like made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. The lung precursor cell is characterized in that the lung precursor cell is induced by inducing human pluripotent stem cells through the following induction stages:
a. inducing the human pluripotent stem cells to differentiate into primitive streak cells;
b. inducing the primitive streak cells to differentiate into definitive endoderm cells;
c. inducing definitive endoderm cells to differentiate into head foregut cells;
d. inducing differentiation of the head foregut cells into lung precursor cells.
2. The alveolar cell is characterized in that the alveolar cell is formed by inducing human pluripotent stem cells through the following induction stages:
a. inducing the human pluripotent stem cells to differentiate into primitive streak cells;
b. inducing the primitive streak cells to differentiate into definitive endoderm cells;
c. inducing definitive endoderm cells to differentiate into head foregut cells;
d. inducing differentiation of the head foregut cells into lung precursor cells.
e. Inducing lung precursor cells to differentiate into alveolar cells.
3. Use of a lung precursor cell according to claim 1 or an alveolar cell according to claim 2 for detecting pulmonary toxicity of a compound.
4. A method for detecting pulmonary toxicity of a compound, comprising the steps of:
s1, inducing human pluripotent stem cells to differentiate into lung precursor cells or alveolar cells;
s2. treating the lung precursor cells or alveolar cells with a compound at a concentration of 1nM to 1mM, preferably 10nM, 50nM, 100nM, 500nM, 1. mu.M, 5. mu.M and 10. mu.M for 1 to 8 days, preferably for 1, 2, 3, 4, 5, 6, 7, 8 days, more preferably for 2 or 8 days;
s3, detecting the concentration of the compound which can affect the basic toxicity index of lung precursor cells or alveolar cells;
s4, detecting the change of the lung precursor cell or alveolar cell biomarker under non-lethal concentration.
5. The method according to claim 4, wherein the basal toxicity index is selected from one or more of the group consisting of cell viability, mitochondrial membrane integrity, active oxygen production, calcium flux changes and lactate dehydrogenase leakage, preferably cell viability and mitochondrial membrane integrity.
6. The method according to claim 5, wherein the method for detecting the viability of the cells is selected from the group consisting of Resazurin, MTT, live/dead cell counting assay, preferably Resazurin.
7. The method according to claim 5, wherein the mitochondrial membrane integrity is detected by a method selected from the group consisting of JC-1 staining, tetramethyl rhodamine methyl ester staining, acridine orange 10-bromononane staining, preferably JC-1 staining.
8. The method of claim 4, wherein the biomarker for lung precursor cells or alveolar cells is selected from the group consisting of NKX2.1, ID2, SFTPC, ABCA3 and NAPSA genes.
9. The method of claim 8, wherein the biomarker for lung precursor cells is selected from the group consisting of NKX2.1, ID2 and SFTPC.
10. The method of claim 4, wherein the method of detecting a change in a biomarker of a lung precursor cell or an alveolar cell comprises fluorescent quantitative PCR.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110598316.5A CN113337453A (en) | 2021-05-31 | 2021-05-31 | Method for detecting pulmonary toxicity of compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110598316.5A CN113337453A (en) | 2021-05-31 | 2021-05-31 | Method for detecting pulmonary toxicity of compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113337453A true CN113337453A (en) | 2021-09-03 |
Family
ID=77472295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110598316.5A Pending CN113337453A (en) | 2021-05-31 | 2021-05-31 | Method for detecting pulmonary toxicity of compounds |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113337453A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202486A1 (en) * | 2004-05-18 | 2007-08-30 | Mitsubishi Pharma Corporation | Method Of Assaying Substance Capable Of Changing Mitochondrial Membrane Potential |
US20140105870A1 (en) * | 2012-09-25 | 2014-04-17 | Yale University | Differentiation of Human IPS Cells to Human Alveolar Type II Via Definitive Endoderm |
CN110522835A (en) * | 2019-07-19 | 2019-12-03 | 江西中医药大学 | Pharmaceutical composition and the preparation method and application thereof with lung mescenchymal stem cell directed differentiation effect in regulation pulmonary fibrosis microenvironment |
-
2021
- 2021-05-31 CN CN202110598316.5A patent/CN113337453A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202486A1 (en) * | 2004-05-18 | 2007-08-30 | Mitsubishi Pharma Corporation | Method Of Assaying Substance Capable Of Changing Mitochondrial Membrane Potential |
US20140105870A1 (en) * | 2012-09-25 | 2014-04-17 | Yale University | Differentiation of Human IPS Cells to Human Alveolar Type II Via Definitive Endoderm |
CN110522835A (en) * | 2019-07-19 | 2019-12-03 | 江西中医药大学 | Pharmaceutical composition and the preparation method and application thereof with lung mescenchymal stem cell directed differentiation effect in regulation pulmonary fibrosis microenvironment |
Non-Patent Citations (2)
Title |
---|
LIU,S.Y. 等: "Development of Human Lung Induction Models for Air Pollutants’Toxicity Assessment", 《ENVIRON. SCI. TECHNOL.》 * |
陈云芳等: "MTT法用于药物对L2细胞毒性的实验研究", 《现代生物医学进展》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sachlos et al. | Embryoid body morphology influences diffusive transport of inductive biochemicals: a strategy for stem cell differentiation | |
Sato et al. | Collagen synthesis is required for ascorbic acid-enhanced differentiation of mouse embryonic stem cells into cardiomyocytes | |
Baldión et al. | Odontoblast‐Like Cells Differentiated from Dental Pulp Stem Cells Retain Their Phenotype after Subcultivation | |
US11649431B2 (en) | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells | |
Kubo et al. | Identification of mesenchymal stem cell (MSC)‐transcription factors by microarray and knockdown analyses, and signature molecule‐marked MSC in bone marrow by immunohistochemistry | |
Zhao et al. | Embryonic myogenesis pathways in muscle regeneration | |
US10711246B2 (en) | Methods and compositions for generating epicardium cells | |
Deng et al. | Hepatic stellate cells modulate the differentiation of bone marrow mesenchymal stem cells into hepatocyte‐like cells | |
EP3134513B1 (en) | Method of producing skin-derived precursor cells | |
JP2021503957A (en) | How to improve the quality of therapeutic cells by measuring glutathione in real time | |
Cieslik et al. | Aberrant differentiation of fibroblast progenitors contributes to fibrosis in the aged murine heart: role of elevated circulating insulin levels | |
Matsuno et al. | Redefining definitive endoderm subtypes by robust induction of human induced pluripotent stem cells | |
CN108938618A (en) | Delay compound and its application of human mesenchymal stem cell aging | |
Perczel-Kovách et al. | STRO-1 positive cell expansion during osteogenic differentiation: A comparative study of three mesenchymal stem cell types of dental origin | |
Roggia et al. | Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase | |
US20230279348A1 (en) | Compositions and methods for obtaining functional basal-like cells | |
CN113215080A (en) | Culture medium and method for inducing differentiation of human pluripotent stem cells into alveolar cells or alveolar organoids | |
Wang et al. | Myocardin-related transcription factor-A is a key regulator in retinoic acid-induced neural-like differentiation of adult bone marrow-derived mesenchymal stem cells | |
Karpukhina et al. | Analysis of genes regulated by DUX4 via oxidative stress reveals potential therapeutic targets for treatment of facioscapulohumeral dystrophy | |
Ido et al. | Expression of chondrogenic potential of mouse trunk neural crest cells by FGF2 treatment | |
Diao et al. | IGF2 enhanced the osteo‐/dentinogenic and neurogenic differentiation potentials of stem cells from apical papilla | |
Kotasová et al. | Phosphoinositide 3‐kinase inhibition enables retinoic acid‐induced neurogenesis in monolayer culture of embryonic stem cells | |
US20210230550A1 (en) | Cell induction method | |
US10006005B2 (en) | Culture medium and method for inducing differentiation of pluripotent stem cells to hepatoblasts | |
Oderberg et al. | Biliary epithelial cells are facultative liver stem cells during liver regeneration in adult zebrafish |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |
|
RJ01 | Rejection of invention patent application after publication |